List of Excipients in Branded Drug JALYN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	JALYN	dutasteride and tamsulosin hydrochloride	0173-0809	BUTYLATED HYDROXYTOLUENE
GlaxoSmithKline LLC	JALYN	dutasteride and tamsulosin hydrochloride	0173-0809	CARRAGEENAN
GlaxoSmithKline LLC	JALYN	dutasteride and tamsulosin hydrochloride	0173-0809	CELLULOSE, MICROCRYSTALLINE
GlaxoSmithKline LLC	JALYN	dutasteride and tamsulosin hydrochloride	0173-0809	FD&C YELLOW NO. 6

JALYN Excipient Strategy and Commercial Opportunities in Fixed-Dose BPH Therapy

Last updated: September 1, 2026

JALYN combines dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg in one oral capsule for men with symptomatic benign prostatic hyperplasia (BPH) and enlarged prostate. Its commercial value is tied to delivery-system integration: dutasteride is presented in a liquid-filled soft gelatin capsule, while tamsulosin is delivered through modified-release beads. This architecture creates opportunities for generic fixed-dose combinations, alternative multiparticulate systems, excipient substitution, manufacturing efficiencies, and differentiated dosage forms.

What is JALYN and how does its dosage form work?

JALYN is a once-daily fixed-dose combination of a 5-alpha-reductase inhibitor and an alpha-1 adrenergic antagonist.

Attribute	JALYN profile
Brand	JALYN
Active ingredients	Dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg
Indication	Symptomatic BPH in men with enlarged prostate
Sponsor	GlaxoSmithKline
FDA application	NDA 022460
Dosage form	Oral hard gelatin capsule containing two internal delivery systems
Dutasteride component	Liquid-filled soft gelatin capsule
Tamsulosin component	Modified-release beads
Administration	One capsule once daily, approximately 30 minutes after the same meal each day
Key handling instruction	Swallow whole; do not chew, crush, or open

The product combines immediate systemic availability of dutasteride with controlled release of tamsulosin. Tamsulosin modified-release technology is important because rapid release can increase peak exposure and raise the risk of dose-related adverse effects, including dizziness and orthostatic hypotension. Dutasteride has a long terminal half-life of approximately five weeks, making formulation differences less likely to dominate short-term exposure but still relevant to long-term bioequivalence and product stability (GlaxoSmithKline, 2023).

What excipients are used in JALYN?

JALYN uses excipients to support two different formulation platforms inside one capsule. The commercial strategy is therefore more complex than combining two conventional immediate-release powders.

Dutasteride softgel system

The dutasteride portion uses a liquid fill enclosed in a soft gelatin shell. Its excipient functions include:

• Solubilizing or dispersing dutasteride, which has very low aqueous solubility.
• Maintaining chemical stability during storage.
• Controlling fill viscosity and capsule-sealing performance.
• Supporting absorption after shell dissolution.
• Preventing oxidation through antioxidant protection where required.

The softgel platform can incorporate lipidic vehicles, surfactants, cosolvents, plasticizers, antioxidants, gelatin, and titanium dioxide or iron oxides for shell opacity and color. Exact excipient selection affects fill uniformity, oxygen exposure, capsule brittleness, dissolution, and interaction with the surrounding hard capsule.

Tamsulosin modified-release bead system

The tamsulosin portion uses multiparticulate beads. Typical functional excipient classes include:

• Core materials, such as microcrystalline cellulose.
• Film-forming polymers.
• pH-dependent or water-permeable release-controlling polymers.
• Plasticizers, such as citrate esters or sebacate derivatives.
• Anti-tacking agents, such as talc or colloidal silicon dioxide.
• Capsule shell materials and colorants.

The bead coating determines the release rate and the impact of food. The commercial target is a reproducible tamsulosin concentration-time profile rather than simple rapid dissolution.

Hard capsule shell

The outer capsule must accommodate the softgel and bead fraction without damaging either component. Relevant shell materials and processing variables include gelatin or an alternative capsule polymer, water content, shell strength, colorants, opacity, printing ink, and dimensional tolerances.

A generic developer must evaluate the capsule as a drug delivery assembly. Matching only the active-ingredient strengths is insufficient.

Which excipient attributes create the strongest development opportunities?

The most valuable opportunities are linked to performance-critical excipients rather than low-cost colorants or capsule components.

Excipient or material function	Commercial value	Main development issue
Dutasteride solubilizer	High	Chemical stability, precipitation, absorption
Dutasteride antioxidant	Medium to high	Oxidative degradation and shelf life
Bead-release polymer	High	Tamsulosin dissolution and pharmacokinetic matching
Plasticizer	Medium	Film flexibility, coating integrity, residual solvents
Anti-tacking agent	Medium	Manufacturing yield and coating uniformity
Capsule shell	Medium	Moisture transfer, brittleness, appearance
Colorant and ink	Low	Supply continuity and cosmetic differentiation
Capsule fill weight	High	Content uniformity and bioequivalence

A developer can create value by replacing a proprietary or supply-constrained excipient with a pharmaceutically equivalent material. The substitution must preserve critical quality attributes, including assay, content uniformity, dissolution, impurities, water activity, and stability.

What formulation patents and intellectual-property barriers affect JALYN?

The core active ingredients are mature molecules. Dutasteride and tamsulosin composition-of-matter protection has largely expired in major markets. The relevant barriers are more likely to involve:

1. Fixed-dose combination claims.
2. Modified-release tamsulosin bead technology.
3. Capsule-in-capsule or dual-compartment arrangements.
4. Manufacturing processes for loading softgel units and beads into one hard capsule.
5. Stability protection for the combined dosage form.
6. Method-of-use claims covering treatment of BPH with the combination.
7. Regulatory exclusivity and Orange Book-listed patents.

The relevant U.S. records are the JALYN NDA, the FDA Orange Book, issued patents assigned to GlaxoSmithKline or related entities, and any Paragraph IV litigation docketed against an ANDA applicant. Patent expiration depends on the specific patent, patent-term adjustment, patent-term extension, terminal disclaimers, and listing status. A commercial launch decision should not rely on the small-molecule expiration dates alone.

What is the Orange Book status of JALYN?

The Orange Book identifies the approved NDA, listed patents, and regulatory exclusivities associated with an FDA-approved product. For JALYN, the central regulatory question is whether an ANDA applicant must certify against active listed patents or can proceed after expiration or delisting.

Regulatory issue	Relevance to a generic JALYN
NDA 022460	Establishes the reference product
Listed patents	Determine Paragraph IV or later-certification exposure
Drug substance patents	Likely less important because the molecules are mature
Dosage-form patents	Potentially important for the dual-delivery capsule
Method-of-use patents	Can affect the proposed label and certification strategy
Exclusivity	May affect ANDA approval timing
Suitability of ANDA	Depends on pharmaceutical equivalence and bioequivalence

An applicant must also assess whether the reference product is eligible for a complex generic pathway. A capsule containing a softgel and modified-release beads may require more extensive comparative characterization than a conventional immediate-release capsule.

When does JALYN lose exclusivity and what generic entry risks exist?

JALYN's commercial exclusivity should be analyzed across four dates:

• Small-molecule patent expiration for dutasteride and tamsulosin.
• JALYN-specific formulation or combination patent expiration.
• Regulatory exclusivity expiration.
• Earliest lawful ANDA launch date after certifications, litigation, or settlement.

The largest generic-entry risk is likely to come from a product that reproduces the therapeutic concept while using a different internal architecture. A competitor may avoid a narrow capsule-assembly claim with:

• A capsule containing coated pellets of both actives.
• A capsule containing tamsulosin beads and a separate dutasteride mini-tablet.
• A dual-layer tablet.
• A bilayer or multilayer multiparticulate system.
• A co-packaged two-capsule regimen, if the regulatory and commercial objectives permit it.

The strongest defense for the originator would generally involve claims covering the combination of active ingredients with specific release characteristics, not merely a capsule containing both drugs.

How can a generic manufacturer design around JALYN excipients?

A design-around program should separate formulation performance from literal excipient identity.

Strategy 1: Match the release profile with different polymers

A generic manufacturer can use a different film-forming or release-controlling polymer if the resulting tamsulosin dissolution and pharmacokinetics meet the required equivalence standards. This approach reduces dependence on the originator's exact coating composition.

Strategy 2: Replace the dutasteride softgel

A developer could formulate dutasteride as a solution, suspension, amorphous dispersion, coated pellet, or mini-tablet. The substitute must address dutasteride's solubility and exposure profile while remaining compatible with the tamsulosin system.

Strategy 3: Use a capsule-in-capsule configuration

A smaller softgel or mini-tablet can be placed inside a hard capsule with tamsulosin beads. This maintains physical separation between incompatible components and may simplify manufacturing.

Strategy 4: Develop a dual-layer tablet

A dual-layer tablet could offer lower packaging and assembly cost. The technical risk is high because the developer must reproduce both dutasteride exposure and tamsulosin modified release in a solid dosage form.

Strategy 5: Improve moisture control

The outer capsule, bead coating, and softgel shell may respond differently to humidity. High-barrier blister packaging, desiccant systems, low-moisture capsule shells, and improved sealing can reduce stability risk and expand geographic distribution.

What FDA pathway applies to a generic JALYN?

An ANDA is the likely U.S. pathway for a product that demonstrates pharmaceutical equivalence and bioequivalence to JALYN. The product must match the reference listed drug in active ingredients, strength, dosage form, route of administration, and labeling, subject to permitted differences under the abbreviated approval framework (U.S. Food and Drug Administration, 2018).

The development package would typically emphasize:

• Comparative dissolution for the tamsulosin modified-release component.
• Dutasteride assay and degradation-product control.
• Content uniformity for both actives.
• Comparative pharmacokinetic studies.
• Food-effect assessment.
• Stability under long-term and accelerated conditions.
• In vitro characterization of bead coating and softgel integrity.
• Extractables and leachables from capsule and packaging materials.
• Manufacturing controls for fill-weight and component segregation.

Because dutasteride is a hazardous reproductive toxicant, manufacturing and packaging controls also have operational importance. Containment, cleaning validation, worker exposure controls, and warning-label requirements can increase capital and compliance costs.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can participate at several levels.

Performance excipients

The highest-value products are polymers, surfactants, lipidic vehicles, antioxidants, and plasticizers that support reproducible release and stability. Suppliers with strong regulatory documentation can compete on more than price.

Ready-to-use coating systems

A ready-to-use modified-release coating system can reduce process development time for tamsulosin beads. The supplier's advantage depends on batch-to-batch consistency, technical support, and regulatory change control.

Low-moisture capsule materials

Capsule shells with controlled moisture transmission can improve stability when the dosage form combines softgel and multiparticulate elements. This opportunity is relevant to both branded lifecycle management and generic development.

Continuous and automated filling

Equipment and process suppliers can target automated placement of softgels and beads into hard capsules. Accurate component counting, low breakage, and online inspection are important commercial differentiators.

Regional sourcing

A second-source excipient strategy can reduce supply-chain exposure. This is particularly relevant for gelatin, titanium dioxide alternatives, specialty polymers, and lipid excipients with limited qualified suppliers.

How does JALYN compare with separate dutasteride and tamsulosin products?

Factor	JALYN	Separate products
Pill burden	One capsule daily	Two dosage units daily
Dose flexibility	Limited	Higher
Manufacturing complexity	High	Lower for each individual product
Adherence proposition	Stronger	More dependent on patient behavior
Formulation freedom	Constrained by fixed combination	Greater
Generic substitution	Complex	Usually simpler
Pricing pressure	Combination-specific	Often stronger due to multiple generic suppliers
Commercial differentiation	Convenience and regimen integration	Dose adjustment and lower cost

JALYN's commercial proposition is strongest when adherence, convenience, and combined therapy are priorities. Its weakness is reduced dose flexibility and higher manufacturing complexity than standalone dutasteride or tamsulosin.

What licensing and partnership opportunities exist?

Potential licensing targets include:

• A generic developer with an established modified-release bead platform.
• A softgel manufacturer with dutasteride experience.
• An excipient supplier with a validated polymer or lipid system.
• A contract development and manufacturing organization capable of capsule-in-capsule assembly.
• A regional commercialization partner with BPH sales infrastructure.
• A packaging company with high-barrier blister technology.

A deal can be structured around formulation know-how, manufacturing rights, territorial commercialization, or a complete ANDA-ready product. The most valuable asset is a formulation with demonstrated bioequivalence and stable commercial-scale manufacturing.

What biosimilar risk applies to JALYN?

JALYN does not create a biosimilar market. It contains chemically synthesized small molecules, not a biologic. Competitive risk comes from generic drugs, authorized generics, alternative fixed-dose combinations, and separate-component substitution.

Key Takeaways

• JALYN is a complex fixed-dose capsule combining dutasteride softgel technology with tamsulosin modified-release beads.
• The principal excipient opportunities involve solubility, controlled release, moisture management, and manufacturing robustness.
• Generic competition is more likely to focus on alternative excipient systems and dosage-form architecture than on the active ingredients.
• FDA approval strategy centers on pharmaceutical equivalence, bioequivalence, dissolution, stability, and component compatibility.
• The commercial value of a JALYN substitute depends on lower manufacturing cost, reliable supply, adequate patent freedom to operate, and successful replication of the tamsulosin release profile.
• Biosimilar risk is not relevant; generic and fixed-dose-combination competition is the principal threat.
• Excipient suppliers can capture value through specialty polymers, lipid vehicles, capsule materials, ready-to-use coatings, and dual-component filling systems.

FAQs

What is the main formulation challenge with JALYN?

The main challenge is integrating a dutasteride softgel and tamsulosin modified-release beads in one capsule while preserving stability, content uniformity, dissolution, and bioequivalence.

Can JALYN be reformulated as a conventional tablet?

Yes, a tablet-based alternative is technically possible, but it would require development of a new release system and may not qualify as an uncomplicated pharmaceutical equivalent to the reference product.

Which excipient class has the greatest commercial value in a JALYN generic?

Modified-release polymers for the tamsulosin beads and lipidic solubilizers for dutasteride have the greatest performance impact and therefore the strongest commercial value.

Is a JALYN generic likely to require specialized manufacturing equipment?

Yes. Manufacturing may require bead coating, softgel production or sourcing, controlled component loading, capsule sealing, inspection, and containment controls for dutasteride.

Does JALYN have biosimilar competition?

No. JALYN contains small-molecule active ingredients. Its relevant competitive threats are generic fixed-dose combinations, standalone dutasteride and tamsulosin, and alternative BPH therapies.

References

1. GlaxoSmithKline. (2023). JALYN (dutasteride and tamsulosin hydrochloride) capsules: Prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2018). Guidance for industry: ANDAs for certain highly purified synthetic peptides. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. U.S. Department of Health and Human Services.